Laboratory Monitoring of Biological Therapies in Rheumatology: The Role of Immunogenicity

Elisa Gremese, Barbara Tolusso, Stefano Alivernini, Maurizio Benucci, Valentina Grossi, Mariangela Manfredi, Arianna Damiani, Maria Infantino, Paolo Moscato, Luigi Cinquanta, Luca Petricca, Anna Laura Fedele, Fabiola Atzeni, Giovanni Minisola, Roberto Verna

Risultato della ricerca: Contributo in rivistaArticolo in rivista

5 Citazioni (Scopus)

Abstract

Biological drugs, such as proteins and immunogens, are increasingly used to treat various diseases, including tumors and autoimmune diseases, and biological molecules have almost completely replaced synthetic drugs in rheumatology. Although biological treatments such as anti-tumor necrosis factor (TNF) drugs seem to be quite safe, they cause some undesirable effects, such as the onset of infections due to weakening of the immune system. Given the biological nature of these drugs, they might be recognized as extraneous; this would induce an immune reaction that neutralizes their effectiveness or lead to more serious consequences. Laboratories play a pivotal role in appropriate therapeutic management. The aim of this review was to underline the production of anti-drug antibodies during treatment with biological drugs and highlight the role of laboratories in ensuring appropriate use of these drugs.
Lingua originaleEnglish
pagine (da-a)101-113
Numero di pagine13
RivistaAnnals of Laboratory Medicine
Volume40
DOI
Stato di pubblicazionePubblicato - 2020

Keywords

  • Anti-drug antibodies
  • Anti-tumor necrosis factor (TNF) drugs
  • Antibodies
  • Biological drugs

Fingerprint Entra nei temi di ricerca di 'Laboratory Monitoring of Biological Therapies in Rheumatology: The Role of Immunogenicity'. Insieme formano una fingerprint unica.

Cita questo